Hypophosphatasia in childhood: Diagnosis to management

Area of Science:

• Genetics and Metabolism
• Bone Biology
• Rare Diseases

Background:

• Hypophosphatasia (HPP) is a rare inherited metabolic bone disorder.
• Caused by loss-of-function mutations in the ALPL gene, leading to deficient tissue-nonspecific alkaline phosphatase (TNSALP) activity.
• Characterized by significant clinical heterogeneity, making diagnosis challenging.

Purpose of the Study:

• To provide an updated review of Hypophosphatasia (HPP).
• Focus on genetic basis, pathophysiology, epidemiology, classification, diagnosis, and management.
• Emphasize enzyme replacement therapy (ERT) and novel diagnostic methods.

Main Methods:

• Literature review of genetic, clinical, and therapeutic data on HPP.
• Analysis of diagnostic criteria including clinical, laboratory, radiographic, and genetic findings.
• Evaluation of the impact of asfotase alfa therapy.

Main Results:

• HPP diagnosis relies on a combination of clinical, laboratory, radiographic, and genetic analyses.
• Asfotase alfa, a bone-targeted recombinant TNSALP, has improved HPP prognosis.
• Early diagnosis is crucial for initiating timely enzyme replacement therapy (ERT).

Conclusions:

• Early and accurate diagnosis of HPP is essential for effective management.
• Enzyme replacement therapy (ERT) with asfotase alfa offers improved outcomes.
• Ongoing research into emerging diagnostic approaches and therapies is vital for HPP patients.